- IN₹1.07tn
- IN₹973.06bn
- IN₹281.63bn
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate
Factbox: Global drugmakers invest billions to boost US presence
Factbox: Global drugmakers invest billions to boost US presence
Brief: Cipla Says Invagen Has Received Establishment Inspection Report From USFDA, Indicating Closure Of Inspection
Brief: Cipla Receives U.S. FDA Approval For Generic Advair Diskus®
Merck licenses experimental HIV pill to generic makers in 129 countries (updated)
New product launches to help India's Cipla weather gRevlimid sales void, analysts say
Brief: Cipla Global CEO Gupta Says Tariffs Is An Evolving Situation, We Will Monitor It
Brief: Cipla Appoints Dinesh Jain As Global CFO
India's Cipla posts another profit decline, names insider Dinesh Jain CFO (updated)
India's Cipla falls after Q1 profit miss
Indian drugmaker Cipla's Q1 profit misses estimates
Brief: Cipla Q1 Consol Net Profit 7.89 Billion Rupees
Preview: India's Cipla faces U.S. headwinds in Q1, likely overshadowing resilient domestic business
India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports
India's pharma stocks fall as Trump outlines steep tariffs on generic drug imports